Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and ¹¹C-Methionine PET/CT for Differentiation of Tumor Recurrence from Radiation Injury in Patients with High-Grade Gliomas

References

1. 1.↵
   2. Verma N,
   3. Cowperthwaite MC,
   4. Burnett MG, et al

   . Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol 2013;15:515–34 doi:10.1093/neuonc/nos307 pmid:23325863

   CrossRefPubMed
2. 2.↵
   2. Hyare H,
   3. Thust S,
   4. Rees J

   . Advanced MRI techniques in the monitoring of treatment of gliomas. Curr Treat Options Neurol 2017;19:11 doi:10.1007/s11940-017-0445-6 pmid:28349351

   CrossRefPubMed
3. 3.↵
   2. Galldiks N,
   3. Law I,
   4. Pope WB, et al

   . The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin 2017;13:386–94 doi:10.1016/j.nicl.2016.12.020 pmid:28116231

   CrossRefPubMed
4. 4.↵
   2. Mangla R,
   3. Singh G,
   4. Ziegelitz D, et al

   . Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 2010;256:575–84 doi:10.1148/radiol.10091440 pmid:20529987

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Patel P,
   3. Baradaran H,
   4. Delgado D, et al

   . MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol 2017;19:118–27 doi:10.1093/neuonc/now148 pmid:27502247

   CrossRefPubMed
6. 6.↵
   2. Barajas RF Jr.,
   3. Chang JS,
   4. Segal MR, et al

   . Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486–96 doi:10.1148/radiol.2532090007 pmid:19789240

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Bisdas S,
   3. Naegele T,
   4. Ritz R, et al

   . Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging. Acad Radiol 2011;18:575–83 doi:10.1016/j.acra.2011.01.018 pmid:21419671

   CrossRefPubMed
8. 8.↵
   2. Deng SM,
   3. Zhang B,
   4. Wu YW, et al

   . Detection of glioma recurrence by ¹¹C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun 2013;34:758–66 doi:10.1097/MNM.0b013e328361f598 pmid:23670103

   CrossRefPubMed
9. 9.↵
   2. Kim YH,
   3. Oh SW,
   4. Lim YJ, et al

   . Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010;112:758–65 doi:10.1016/j.clineuro.2010.06.005 pmid:20619531

   CrossRefPubMed
10. 10.↵
    2. Hojjati M,
    3. Garg V,
    4. Badve CA, et al

    . Differentiation of recurrent spinal ependymoma from postradiation treatment necrosis through multiparametric PET-MR and perfusion MRI. Clin Imaging 2017;41:48–52 doi:10.1016/j.clinimag.2016.09.002 pmid:27816875

    CrossRefPubMed
11. 11.↵
    2. Wang X,
    3. Hu X,
    4. Xie P, et al

    . Comparison of magnetic resonance spectroscopy and positron emission tomography in detection of tumor recurrence in posttreatment of glioma: a diagnostic meta-analysis. Asia Pac J Clin Oncol 2015;11:97–105 doi:10.1111/ajco.12202 pmid:24783970

    CrossRefPubMed
12. 12.↵
    2. DeLong ER,
    3. DeLong DM,
    4. Clarke-Pearson DL

    . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45 doi:10.2307/2531595 pmid:3203132

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Nihashi T,
    3. Dahabreh IJ,
    4. Terasawa T

    . Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol 2013;34:944–50, S1–11 doi:10.3174/ajnr.A3324 pmid:23124638

    Abstract/FREE Full Text
14. 14.↵
    2. Minamimoto R,
    3. Saginoya T,
    4. Kondo C, et al

    . Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment. PLoS One 2015;10:e0132515 doi:10.1371/journal.pone.0132515 pmid:26167681

    CrossRefPubMed
15. 15.↵
    2. Skvortsova TY,
    3. Brodskaya ZL,
    4. Gurchin AF

    . PET using 11C-methionine in recognition of pseudoprogression in cerebral glioma after combined treatment [in English, Russian]. Zh Vopr Neirokhir Im N N Burdenko 2014;78:50–58 doi:10.17116/neiro201478650-54 pmid:25406809

    CrossRefPubMed
16. 16.↵
    2. Tsuyuguchi N,
    3. Takami T,
    4. Sunada I, et al

    . Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery: in malignant glioma. Ann Nucl Med 2004;18:291–96 doi:10.1007/BF02984466 pmid:15359921

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Herrmann K,
    3. Czernin J,
    4. Cloughesy T, et al

    . Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol 2014;16:603–09 doi:10.1093/neuonc/not166 pmid:24305722

    CrossRefPubMed
18. 18.↵
    2. Terakawa Y,
    3. Tsuyuguchi N,
    4. Iwai Y, et al

    . Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694–99 doi:10.2967/jnumed.107.048082 pmid:18413375

    Abstract/FREE Full Text
19. 19.↵
    2. Martínez-Amador N,
    3. Jimenez-Bonilla J,
    4. Martínez-Rodriguez I, et al

    . Value of the visual and semiquantitative analysis of carbon-11-methionine PET/CT in brain tumors' recurrence versus post-therapeutic changes. Nucl Med Commun 2017;38:1125–32 doi:10.1097/MNM.0000000000000754 pmid:28906344

    CrossRefPubMed
20. 20.↵
    2. Kaschten B,
    3. Stevenaert A,
    4. Sadzot B, et al

    . Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85 pmid:9591574

    Abstract/FREE Full Text
21. 21.↵
    2. Tripathi M,
    3. Sharma R,
    4. Varshney R, et al

    . Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 2012;37:158–63 doi:10.1097/RLU.0b013e318238f51a pmid:22228339

    CrossRefPubMed
22. 22.↵
    2. Deuschl C,
    3. Kirchner J,
    4. Poeppel TD, et al

    . ¹¹C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging 2018;45:593–601 doi:10.1007/s00259-017-3916-9 pmid:29282517

    CrossRefPubMed
23. 23.↵
    2. Young RJ,
    3. Gupta A,
    4. Shah AD, et al

    . MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging 2013;37:41–49 doi:10.1016/j.clinimag.2012.02.016 pmid:23151413

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Prager AJ,
    3. Martinez N,
    4. Beal K, et al

    . Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 2015;36:877–85 doi:10.3174/ajnr.A4218 pmid:25593202

    Abstract/FREE Full Text
25. 25.↵
    2. D'Souza MM,
    3. Sharma R,
    4. Jaimini A, et al

    . ¹¹C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas. Clin Nucl Med 2014;39:791–98 doi:10.1097/RLU.0000000000000532 pmid:25036022

    CrossRefPubMed
26. 26.↵
    2. Dandois V,
    3. Rommel D,
    4. Renard L, et al

    . Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Neuroradiol 2010;37:89–97 doi:10.1016/j.neurad.2009.04.005 pmid:19570578

    CrossRefPubMed
27. 27.↵
    2. Rausch I,
    3. Rischka L,
    4. Ladefoged CN, et al

    . PET/MRI for oncologic brain imaging: a comparison of standard MR-based attenuation corrections with a model-based approach for the Siemens mMR PET/MR System. J Nucl Med 2017;58:1519–25 doi:10.2967/jnumed.116.186148 pmid:28254872

    Abstract/FREE Full Text
28. 28.↵
    2. Ladefoged CN,
    3. Andersen FL,
    4. Kjaer A, et al

    . RESOLUTE PET/MRI attenuation correction for O-(2-¹⁸F-fluoroethyl)-L-tyrosine (FET) in brain tumor patients with metal implants. Front Neurosci 2017;11:453 doi:10.3389/fnins.2017.00453 pmid:28848379

    CrossRefPubMed